Prostate MRI

Multiparametric prostate MRI for elevated PSA investigation, biopsy guidance planning, and active surveillance of known prostate lesions.

MIRAI Clinic's prostate MRI uses a multiparametric protocol combining T2-weighted, diffusion-weighted (DWI with ADC mapping), and dynamic contrast-enhanced sequences to characterise prostatic lesions according to the PI-RADS v2.1 classification system. This approach has largely replaced the traditional TRUS-guided systematic biopsy pathway for initial prostate cancer investigation in men with elevated or rising PSA. The examination is performed on the BioMatrix scanner using a phased-array surface coil without an endorectal coil, improving patient comfort while maintaining diagnostic image quality. Patients are asked to abstain from ejaculation for three days before the scan and to arrive with a comfortably full bladder. No bowel preparation is required. An antispasmodic agent may be administered to reduce peristaltic artefact. The PI-RADS score stratifies lesions from 1 (clinically significant cancer highly unlikely) to 5 (highly likely), directly informing the decision to proceed with targeted biopsy, continue surveillance, or reassure the patient. For scores of 3 or above, MIRAI can coordinate targeted biopsy and urological consultation through its referral network.